In interviews with STAT Senior Writer Adam Feuerstein, who recorded the confrontation, Cohodes, and MiMedx CEO Parker "Pete" Petit, it becomes clear they each perceive the event differently.
In an interview, Slavitt highlighted some of the health tech startups that he thinks are addressing the needs of Medicaid patients by providing much-needed services behind their technologies.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This year, more than any other, there was an abundance of women at events surrounding the J.P. Morgan Healthcare conference. While the main event featured a mere 20 total women CEOs, the tone on the outside of the Westin St. Francis hotel was somewhat better than in prior years.
Sanofi Chief Medical Officer Dr. Ameet Nathwani expressed excitement about the technology developments that stand to benefit drug development in a fireside chat at StartUp Health Festival this week but noted that integration poses its own set of challenges.
Although their figures differ, StartUp Health and Rock Health both noted in their end-of-year reports that digital health dealflow reached a new peak in 2017.
In a rather uncharacteristic breakout session at the J.P. Morgan Healthcare Conference, short seller Marc Cohodes and MiMedx CEO Parker "Pete" Petit got into an argument over the medical device company's business practices and it was captured on Periscope.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Biotech insiders at a panel discussion shared tidbits of information that reveals a lot about the investment landscape in biotech and pharma.
With the tax reform bill that recently passed and the dramatic rate-cut for overseas cash being repatriated to 14.5 percent from 35 percent, it's no surprise that M&A deals will abound.
B Capital Group Partner Gavin Teo said tax reform and a more liberal FDA are helping to make technologies supporting drug research and development more attractive to investors.
It’s an incredible time for the life sciences, panelists at a Biotech Showcase session on Monday agreed. However, it comes with a catch: The greater the miracle, the greater the anguish when a patient can’t afford or can’t access the drug.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Omar Ishrak highlights a few products with which Medtronic hopes to succeed in value-based care and responds to criticism about how it approaches high-growth companies from an acquisitions.
San Diego, California-based Genalyte has spent 10 years developing its lab-on-a-chip technology. Now it’s ready, to try it out on J.P. Morgan investors, quite literally.
A French investment banker attempts to explain how the new France is a haven for startups and biotech innovation, and a place where U.S. investors stand to make a ton of money.